Remove Biotechnology Remove IT partnerships Remove Legal
article thumbnail

Growth Perspectives: Key Highlights from DCAT 2024

Frost & Sullivan

FUJIFILM Diosynth Biotechnologies invested $1.6 Growth Opportunity 2 – Medical Cannabidiol (CBD) Global regulatory shifts toward legalizing medical cannabis and CBD products highlight the growing interest in cannabis-based treatments.